C Diff Foundation

Results on this investigational antibiotic in its phase 2A study were presented at the C Diff. Conference today.

Presentation highlights from the second and final day of the 9th Annual International C. diff Conference & Health Expo.

At the C Diff Foundation Conference, promising investigational modalities and therapies, as well as better treatment approaches are all being discussed in hopes of some real inroads being made in this field in the near future.

Although no longer indicated as a first-line therapy, metronidazole still has therapeutic benefits and can serve patients in certain settings and circumstances.

Highlights from some of this afternoon's presenters at the 9th Annual International C diff Conference & Health Expo.

Highlights from the morning session of the C Diff Foundation Conference included data about Pfizer's investigational vaccine, insights about Seres Therapeutics microbiome therapeutic, and a look at CDI incidence rates around COVID-19.

Curtis Donskey, MD, discussed his efforts to encourage C. diff patients and providers to do their part to reduce infection and reinoculation.

The development of these programs are being looked at for private practices in the community settings to try to create better prescribing practices and avoid the potential progression to health care associated infections.

The organization is hosting its 9th Annual International C Diff Conference and Health EXPO on Thursday and Friday this week. The conference is virtual and free to the public.

This event will be a free, virtual event in July with expert speakers and survivors.

Neotrope announced the C diff Foundation as a recipient of the JL Simmons NonProfit PR Grant.

The updated guidelines recommend targeting those with active infection and avoiding treatment of “carriers” of C difficile who are colonized but not symptomatic.

Barley Chironda, RPN, CIC, explains the role that nurses play in disinfection practices at health care facilities.

Barley Chironda, RPN, CIC, infection control specialist at Clorox Healthcare, explains how cell phones and smart devices can potentially serve as a vector for C. diff.

Barley Chironda, RPN, CIC, explains why current environmental disinfection practices aren’t making the cut.

Dr. Richard Vickers, discusses C. difficile rates in the United Kingdom.

Barley Chironda, RPN, CIC, discusses different high-touch surfaces in hospital rooms that are known to harbor pathogenic bacteria.

Glenn Tillotson, PhD, FIDSA, provides insight into the growing problem and cost of antimicrobial resistance.

Dr. Richard Vickers, discusses what the next steps are for Summit Therapeutic’s ridinilazole.

Edmond Hooker, MD, DrPH, stresses that the FDA and the CDC need to intervene to ensure that hospital mattresses get cleaned appropriately.

Barley Chironda, RPN, CIC, stresses that understanding what motivates health care workers’ actions is crucial for reducing C. diff rates in hospitals.

Glenn Tillotson, PhD, FIDSA, explains how costs associated with Clostridium difficile compare with other problematic health care-associated infections.

Richard Haupt, MD, MPH, explains why it’s harder to cover adults rather than children when it comes to vaccination.

Edmond Hooker, MD, DrPH, discusses a study that assessed the use of mattress covers in hospitals to cut down on CDI rates.

Barley Chironda, RPN, CIC, discusses why some health care workers are not practicing good hand hygiene and ways to motivate them to do so.

Dr. Richard Vickers, explains how ridinilazole affected the gut microbiome in participants of a phase 2 study.

Glenn Tillotson, PhD, FIDSA, discusses the costs of drug development.

In the USA: Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year according to a study released in 2015 by the Centers for Disease Control and Prevention.

Edmond Hooker, MD, DrPH, discusses how contaminated hospital mattresses act as a vector for spreading drug-resistant infections.

Dr. Richard Vickers, discusses how ridinilazole showed superior efficacy for the treatment of C. diff when compared with vancomycin in a phase 2 study.